Emily Culme-Seymour, MSc, PhD

Emily Culme-Seymour, MSc, PhD

Dr. Culme-Seymour has a background in chemistry (BSc, University of Edinburgh and MSc, University College London) and holds a PhD in stem cell bioprocessing from the Advanced Centre for Biochemical Engineering, University College London.

In a step away from the laboratory bench, she is a Director of the London Regenerative Medicine Network (LRMN). Founded in 2005 by two internationally recognized leaders in the field, Dr. Stephen Minger (GE Healthcare) and Prof. Chris Mason (UCL), the LRMN has over 6,000 members and is firmly committed to helping facilitate the building of a competitive and sustainable international cell and gene therapy industry, one that will deliver safe, effective and affordable advanced therapies for the benefit of all.

Dr. Culme-Seymour represents the LRMN on a number of UK and EU consortium projects looking at cell therapy technologies and business modelling, and is a regular author of leading industry-orientated publications in high impact journals including Regenerative Medicine and Cell Stem Cell.

She also sits on the International Society for Cell Therapy’s (ISCT) Executive Committee as Global Treasurer, and uses her knowledge of the cell therapy and regenerative medicine field to advise the internationally-acknowledged stem cell and regenerative medicine lawyers, Lawford Davies Denoon (London, UK), on the more scientific aspects of specific cases.

Julian Mason, PhD

Julian Mason, PhD

For over a decade, Dr. Mason has been involved with applying his computer modeling and data analysis skills to the financial markets. He is a member of The Society of Technical Analysists (STA) and now freelances as an advanced top-down technical analyst (market, sector and instrument), developing a range of financial models to determine whether a company is deemed to be either under- or indeed over-valued. Work requires visualization, modeling and interpretation of complex financial data sets, for both trend analysis and price target projections . To enhance the proprietary chart indicators, which when primed with suitable working parameters, provide excellent analysis tools, Dr. Mason has become highly experienced in scripting complex custom hybrid and unique charting indicators, for trend analysis, which are optimized for performance by automated back testing using historical data over a range of market conditions. For stock market trading purposes, Dr. Mason specializes in writing coherent entry and exit trading strategies, across differing market conditions, to maximize profitability and minimize risk / reward ratios. Such strategies include processes to dynamically lock in profits. Current work includes development and maintenance of specific market indices, including the CTI (Cell Therapy Index) for Proteus, LLC.

Dr. Mason has a strong background and wide-ranging skillsets in applied physics, IT and analysis. After completing his PhD, Dr. Mason commenced work at Kingston University as a Course Director delivering predominately computer languages, scripted animation techniques, electronics / interfacing, mathematics and applied physics. He has since moved away from lecturing and is now concentrating on contract research. In 1998, Dr. Mason became a director at Figleaf IT Ltd. His primary function was to manage and author company specific interactive multimedia applications for in-house use by a number of multinationals including: Dell, Oracle, Nokia and Oki. After leaving Figleaf IT Ltd, Dr. Mason became a freelance multimedia developer, specializing in scripted interactive environments; creating e-commerce websites; developing information portals and data mining tools; and more recently in developing apps, for both smart phones and tablets.